Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial

Editas Medicine has the regulatory blessing to test its experimental gene-editing therapy in humans, and a $25 million check from its partner, Allergan, for hitting that milestone. But Editas will conduct the clinical trial without Katrine Bosley, the CRISPR biotech’s top executive for nearly the last five years.